{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:37:36Z","timestamp":1794926256455,"version":"4.9.1"},"update-to":[{"DOI":"10.1371\/journal.ppat.1011469","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000}}],"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068614"],"award-info":[{"award-number":["UM1 AI068614"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068618"],"award-info":[{"award-number":["UM1 AI068618"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068619"],"award-info":[{"award-number":["UM1 AI068619"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068613"],"award-info":[{"award-number":["UM1 AI068613"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068617"],"award-info":[{"award-number":["UM1 AI068617"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30 AI027757"],"award-info":[{"award-number":["P30 AI027757"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI152115"],"award-info":[{"award-number":["R01 AI152115"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"name":"South African Research Chairs Initiative of the Department of Science and Innovation and the National Research Foundation","award":["98341"],"award-info":[{"award-number":["98341"]}],"id":[{"id":"https:\/\/ror.org\/048kh7197","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bill & Melinda Gates Foundation\u2019s Collaboration for AIDS Vaccine Discovery","award":["1032144"],"award-info":[{"award-number":["1032144"]}],"id":[{"id":"https:\/\/ror.org\/0456r8d26","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016 and 2020 showed for the first time that passively administered broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition against bnAb-sensitive viruses. HIV-1 viruses isolated from AMP participants who acquired infection during the study in the sub-Saharan African (HVTN 703\/HPTN 081) and the Americas\/European (HVTN 704\/HPTN 085) trials represent a panel of currently circulating strains of HIV-1 and offer a unique opportunity to investigate the sensitivity of the virus to broadly neutralizing antibodies (bnAbs) being considered for clinical development. Pseudoviruses were constructed using envelope sequences from 218 individuals. The majority of viruses identified were clade B and C; with clades A, D, F and G and recombinants AC and BF detected at lower frequencies. We tested eight bnAbs in clinical development (VRC01, VRC07-523LS, 3BNC117, CAP256.25, PGDM1400, PGT121, 10\u20131074 and 10E8v4) for neutralization against all AMP placebo viruses (n = 76). Compared to older clade C viruses (1998\u20132010), the HVTN703\/HPTN081 clade C viruses showed increased resistance to VRC07-523LS and CAP256.25. At a concentration of 1\u03bcg\/ml (IC80), predictive modeling identified the triple combination of V3\/V2-glycan\/CD4bs-targeting bnAbs (10-1074\/PGDM1400\/VRC07-523LS) as the best against clade C viruses and a combination of MPER\/V3\/CD4bs-targeting bnAbs (10E8v4\/10-1074\/VRC07-523LS) as the best against clade B viruses, due to low coverage of V2-glycan directed bnAbs against clade B viruses. Overall, the AMP placebo viruses represent a valuable resource for defining the sensitivity of contemporaneous circulating viral strains to bnAbs and highlight the need to update reference panels regularly. Our data also suggests that combining bnAbs in passive immunization trials would improve coverage of global viruses.<\/jats:p>","DOI":"10.1371\/journal.ppat.1011469","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T14:22:02Z","timestamp":1688048522000},"page":"e1011469","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":63,"title":["Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3037-1243","authenticated-orcid":true,"given":"Nonhlanhla N.","family":"Mkhize","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E. J.","family":"Yssel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haajira","family":"Kaldine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca T.","family":"van Dorsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-8271","authenticated-orcid":true,"given":"Amanda S.","family":"Woodward Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Beaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Matten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen","family":"Lambson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tandile","family":"Modise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence","family":"Kgagudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan H.","family":"Westfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena E.","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette","family":"Korber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutendo E.","family":"Mapengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Domin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"DeCamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asanda","family":"Gwashu-Nyangiwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwayhida","family":"Thebus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonkululeko","family":"Ndabambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyaradzo","family":"Mgodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Karuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilatha","family":"Edupuganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Juliana","family":"McElrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3961-7828","authenticated-orcid":true,"given":"Lynn","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"issue":"46","key":"ppat.1011469.ref001","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"B Moldt","year":"2012","journal-title":"Proc National Acad Sci"},{"issue":"243","key":"ppat.1011469.ref002","doi-asserted-by":"crossref","first-page":"243ra88","DOI":"10.1126\/scitranslmed.3008992","article-title":"Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.","volume":"6","author":"A Pegu","year":"2014","journal-title":"Sci Transl Med."},{"issue":"7601","key":"ppat.1011469.ref003","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","article-title":"A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges","volume":"533","author":"R Gautam","year":"2016","journal-title":"Nature"},{"issue":"16","key":"ppat.1011469.ref004","doi-asserted-by":"crossref","first-page":"8334","DOI":"10.1128\/JVI.00908-15","article-title":"Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection","volume":"89","author":"KO Saunders","year":"2015","journal-title":"J Virol"},{"issue":"11","key":"ppat.1011469.ref005","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"L Corey","year":"2021","journal-title":"New Engl J Med"},{"issue":"7","key":"ppat.1011469.ref006","doi-asserted-by":"crossref","first-page":"e1005742","DOI":"10.1371\/journal.ppat.1005742","article-title":"Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.","volume":"12","author":"C Rademeyer","year":"2016","journal-title":"Plos Pathog."},{"issue":"9","key":"ppat.1011469.ref007","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/nm.2203","article-title":"Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level","volume":"16","author":"EM Bunnik","year":"2010","journal-title":"Nat Med"},{"issue":"S1","key":"ppat.1011469.ref008","doi-asserted-by":"crossref","first-page":"A224","DOI":"10.1089\/aid.2014.5490.abstract","article-title":"Adaptation of HIV-1 Envelope Glycoprotein gp120 to Humoral Immunity over the Course of the Epidemic","volume":"30","author":"M Bouvin-Pley","year":"2014","journal-title":"Aids Res Hum Retrov"},{"issue":"6929","key":"ppat.1011469.ref009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"X Wei","year":"2003","journal-title":"Nature"},{"issue":"16","key":"ppat.1011469.ref010","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1128\/JVI.00757-08","article-title":"Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection.","volume":"82","author":"EM Bunnik","year":"2008","journal-title":"J Virol"},{"issue":"19","key":"ppat.1011469.ref011","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1128\/JVI.00141-06","article-title":"Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity","volume":"80","author":"M Sagar","year":"2006","journal-title":"J Virol"},{"issue":"19","key":"ppat.1011469.ref012","doi-asserted-by":"crossref","first-page":"e00991","DOI":"10.1128\/JVI.00991-17","article-title":"Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments","volume":"91","author":"P Hraber","year":"2017","journal-title":"J Virol"},{"issue":"5","key":"ppat.1011469.ref013","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies","volume":"88","author":"A deCamp","year":"2014","journal-title":"J Virol"},{"key":"ppat.1011469.ref014","doi-asserted-by":"crossref","first-page":"712122","DOI":"10.3389\/fimmu.2021.712122","article-title":"Broadly Neutralizing Antibodies for HIV-1 Prevention.","volume":"12","author":"SR Walsh","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"ppat.1011469.ref015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev-med-110118-045506","article-title":"Broadly Neutralizing Antibodies for HIV Prevention.","volume":"71","author":"ST Karuna","year":"2020","journal-title":"Annu Rev Med."},{"issue":"3","key":"ppat.1011469.ref016","doi-asserted-by":"crossref","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.","volume":"12","author":"K Wagh","year":"2016","journal-title":"Plos Pathog."},{"issue":"5","key":"ppat.1011469.ref017","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/JVI.03136-14","article-title":"Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes","volume":"89","author":"R Kong","year":"2015","journal-title":"J Virol"},{"issue":"319","key":"ppat.1011469.ref018","doi-asserted-by":"crossref","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.","volume":"7","author":"RM Lynch","year":"2015","journal-title":"Sci Transl Med."},{"issue":"7","key":"ppat.1011469.ref019","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1128\/JVI.02658-10","article-title":"Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop.","volume":"85","author":"PL Moore","year":"2011","journal-title":"J Virol"},{"issue":"49","key":"ppat.1011469.ref020","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"D Sok","year":"2014","journal-title":"Proc National Acad Sci"},{"issue":"1","key":"ppat.1011469.ref021","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","article-title":"HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.","volume":"25","author":"CA Bricault","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"1","key":"ppat.1011469.ref022","doi-asserted-by":"crossref","first-page":"107488","DOI":"10.1016\/j.celrep.2020.03.052","article-title":"Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition.","volume":"31","author":"J Gorman","year":"2020","journal-title":"Cell Reports."},{"issue":"1","key":"ppat.1011469.ref023","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency","volume":"90","author":"NA Doria-Rose","year":"2016","journal-title":"J Virol"},{"issue":"1","key":"ppat.1011469.ref024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12977-021-00556-2","article-title":"Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities.","volume":"18","author":"R Mullick","year":"2021","journal-title":"Retrovirology"},{"issue":"6049","key":"ppat.1011469.ref025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing","volume":"333","author":"X Wu","year":"2011","journal-title":"Science"},{"issue":"5993","key":"ppat.1011469.ref026","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01","volume":"329","author":"T Zhou","year":"2010","journal-title":"Science"},{"issue":"7557","key":"ppat.1011469.ref027","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"M Caskey","year":"2015","journal-title":"Nature"},{"issue":"7613","key":"ppat.1011469.ref028","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"JF Scheid","year":"2016","journal-title":"Nature"},{"issue":"6623","key":"ppat.1011469.ref029","doi-asserted-by":"crossref","first-page":"eadd6502","DOI":"10.1126\/science.add6502","article-title":"Vaccination induces HIV broadly neutralizing antibody precursors in humans","volume":"378","author":"DJ Leggat","year":"2022","journal-title":"Science"},{"issue":"12","key":"ppat.1011469.ref030","doi-asserted-by":"crossref","first-page":"e1001228","DOI":"10.1371\/journal.ppat.1001228","article-title":"HIV-1 Envelope Subregion Length Variation during Disease Progression.","volume":"6","author":"ME Curlin","year":"2010","journal-title":"Plos Pathog."},{"issue":"21","key":"ppat.1011469.ref031","doi-asserted-by":"crossref","first-page":"12623","DOI":"10.1128\/JVI.01705-14","article-title":"Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies","volume":"88","author":"P Hraber","year":"2014","journal-title":"J Virol"},{"issue":"14","key":"ppat.1011469.ref032","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1128\/JVI.02619-05","article-title":"Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1","volume":"80","author":"CP Krachmarov","year":"2006","journal-title":"J Virol"},{"issue":"10","key":"ppat.1011469.ref033","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1128\/JVI.78.10.5205-5215.2004","article-title":"The V1\/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection","volume":"78","author":"A Pinter","year":"2004","journal-title":"J Virol"},{"issue":"2","key":"ppat.1011469.ref034","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1128\/JVI.02143-07","article-title":"The First Hypervariable Region of the gp120 Env Glycoprotein Defines the Neutralizing Susceptibility of Heterologous Human Immunodeficiency Virus Type 1 Isolates to Neutralizing Antibodies Elicited by the SF162gp140 Immunogen","volume":"82","author":"LK Ching","year":"2008","journal-title":"J Virol"},{"issue":"8","key":"ppat.1011469.ref035","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02249-17","article-title":"Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions","volume":"92","author":"E Rujas","year":"2018","journal-title":"J Virol"},{"issue":"7524","key":"ppat.1011469.ref036","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"SY Ko","year":"2014","journal-title":"Nature"},{"issue":"2","key":"ppat.1011469.ref037","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"J Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"1","key":"ppat.1011469.ref038","doi-asserted-by":"crossref","first-page":"1946918","DOI":"10.1080\/19420862.2021.1946918","article-title":"A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention.","volume":"13","author":"YD Kwon","year":"2021","journal-title":"Mabs"},{"issue":"21","key":"ppat.1011469.ref039","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo","volume":"88","author":"RS Rudicell","year":"2014","journal-title":"J Virol"},{"issue":"1","key":"ppat.1011469.ref040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12977-018-0439-9","article-title":"Engineering multi-specific antibodies against HIV-1.","volume":"15","author":"NN Padte","year":"2018","journal-title":"Retrovirology"},{"issue":"1","key":"ppat.1011469.ref041","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.","volume":"15","author":"MR Gaudinski","year":"2018","journal-title":"Plos Med."},{"issue":"12","key":"ppat.1011469.ref042","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120\u2013MF59 in Adults","volume":"384","author":"GE Gray","year":"2021","journal-title":"New Engl J Med"},{"issue":"5993","key":"ppat.1011469.ref043","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1","volume":"329","author":"X Wu","year":"2010","journal-title":"Science"},{"issue":"7424","key":"ppat.1011469.ref044","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"J Huang","year":"2012","journal-title":"Nature"},{"issue":"6049","key":"ppat.1011469.ref045","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding.","volume":"333","author":"JF Scheid","year":"2011","journal-title":"Science"},{"issue":"9","key":"ppat.1011469.ref046","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","volume":"28","author":"PB Gilbert","year":"2022","journal-title":"Nat Med"},{"issue":"16","key":"ppat.1011469.ref047","first-page":"10103","article-title":"Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1","volume":"79","author":"JR Mascola","year":"2005","journal-title":"Vaccines. J Virol"},{"issue":"1\u20132","key":"ppat.1011469.ref048","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2011.09.007","article-title":"Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells","volume":"375","author":"CA Todd","year":"2012","journal-title":"J Immunol Methods"},{"key":"ppat.1011469.ref049","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"key":"ppat.1011469.ref050","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"DC Montefiori","year":"2008","journal-title":"Methods Mol Biology Clifton N J"},{"issue":"3","key":"ppat.1011469.ref051","doi-asserted-by":"crossref","first-page":"e9490","DOI":"10.1371\/journal.pone.0009490","article-title":"FastTree 2 \u2013Approximately Maximum-Likelihood Trees for Large Alignments","volume":"5","author":"MN Price","year":"2010","journal-title":"Plos One"},{"issue":"1","key":"ppat.1011469.ref052","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1002\/cpbi.96","article-title":"Using ggtree to Visualize Data on Tree-Like Structures","volume":"69","author":"G. Yu","year":"2020","journal-title":"Curr Protoc Bioinform"},{"issue":"3","key":"ppat.1011469.ref053","doi-asserted-by":"crossref","first-page":"e1006860","DOI":"10.1371\/journal.ppat.1006860","article-title":"Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.","volume":"14","author":"K Wagh","year":"2018","journal-title":"Plos Pathog."},{"key":"ppat.1011469.ref054","author":"A Signorell","year":"2021","journal-title":"DescTools: Tools for Descriptive Statistics R package version 0.99.40"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1011469","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1011469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T22:11:51Z","timestamp":1702678311000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1011469"}},"subtitle":[],"editor":[{"given":"Susan R.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1011469","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.ppat.1011469.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.ppat.1011469.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.ppat.1011469.g003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.ppat.1011469.g004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.ppat.1011469.g005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.ppat.1011469.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.ppat.1011469.s002","asserted-by":"subject"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}